Cancer researchers have a multitude of tools to study tumors. Histological staining uses dyes to make different kinds of ...

Tissue staining is a cornerstone of medical diagnostics, used to highlight cellular structures and render tissue features ...

Discover a study that identified how patients with eosinophilic oesophagitis cope with their daily symptoms. Learn more.

Patients with eosinophilic granulomatosis with polyangiitis experienced significant improvements in a variety of outcomes ...

China: A new study published in BMC Pulmonary Medicine highlights a significant association between elevated blood eosinophil ...

A groundbreaking study led by National Jewish Health researchers suggests that the skin may serve as a potential biomarker for a chronic allergic disease of the esophagus called eosinophilic ...

After completing the 5.6km first bored tunnel of the UK’s HS2 Bromford Tunnel, linking North Warwickshire and Birmingham, HS2 ...

The Food and Drug Administration (FDA) has granted Orphan Drug designation to NS-229 for the treatment of eosinophilic granulomatosis with polyangiitis (EGPA).

References: Nucala (mepolizumab) approved by US FDA for use in adults with chronic obstructive pulmonary disease (COPD). News release. GSK. May 22, 2025.

FDA approves mepolizumab (Nucala; GSK) as the first monthly biologic for chronic obstructive pulmonary disease (COPD), significantly reducing exacerbations in patients with an eosinophilic phenotype.

New findings from the MATINEE and COPD-HELP studies suggest mepolizumab could reduce exacerbations and improve quality of life in patients with eosinophilic chronic obstructive pulmonary disease ...

On 18 May 2025, at the American Thoracic Society International Conference, held in San Francisco, California, post hoc findings from the Phase IIa COURSE trial (NCT04039113) shed light on the ...